Erkki Ruoslahti

Erkki Ruoslahti is the founder of Telios Pharmaceuticals, Inc. (founded in 1987), Targeted Molecules Corp.
(founded in 2000), and Cend Therapeutics, Inc. (founded in 2015).
He holds the title of Director at Telios Pharmaceuticals, Inc. from 1987 to 1995, Director at Targeted Molecules Corp.
from 2000 to 2002, and previously served as the Executive Chairman at Cend Therapeutics, Inc. Dr. Ruoslahti is also the founder of FIBRX Derm, Inc., Center For Nanomedicine, and Impilo Therapeutics, Inc. Dr. Ruoslahti's current job(s) include being a Professor at the University of California, Berkeley, a Member of the National Academy of Sciences, a Member of the American Academy of Arts & Sciences, a Member of the National Academy of Medicine (United States), and a Member of the European Molecular Biology Organization.
Dr. Ruoslahti's former job(s) include being the President & Chief Executive Officer of Sanford Burnham Prebys Medical Discovery Institute from 1976 to 2020, Director at Advance Technologies, Inc. from 2005 to 2008, Director at Canji, Inc. from 1993 to 1996, Independent Director at Astellas Institute for Regenerative Medicine from 2005 to 2011, Independent Director at Lisata Therapeutics, Inc. from 2022 to 2023, and Professor at the University of California, Santa Barbara from 2005 to 2015.
Dr. Ruoslahti obtained a doctorate degree from the University of Helsinki.